This week we come to meta-analyse, strikingly late, the cornerstone of all CKD treatments. Are you still in doubt? We need ACEing CKD to the end of GFR, and beyond
Background
This week, we will discuss the phase 3 ORIGIN3 trial of atacicept, an APRIL/BAFF inhibitor for use in IgAN.
news
Day 3 of Kidney Week. Sibeprenlimab and Balcinrenone on NEJM and Lancet, plus a couple of other non-kidneywk studies.
Background, news
in this edition: Fish Oil, GBD, Flozination meta-analysis, CHW intervention in Hispanic/Latino patients, and much more
Background, news
in this edition: Atacicept in IgAN; Albuminuria as a surrogate outcome, Renal Remission and additional CONFIDENCE analysis
